Recall of Prostate Health Supplement

Recall of U-Prosta of hidden terazosin, a prescription drug ingredient

/ Author:  / Reviewed by: Joseph V. Madia, MD

USA Far Ocean Group Inc. announced that it is conducting a voluntary nationwide recall of the Company's supplement product sold under the name “U-Prosta Natural support for prostate health”.

The Company has been informed by representatives of the U.S. Food and Drug Administration (FDA) that lab analysis by FDA of U-Prosta samples found the product contains terazosin, the active ingredient of an FDA-approved drug used to treat Benign Prostatic Hyperplasia (enlarged prostate), making U-Prosta an unapproved drug.

The most likely adverse health consequences that could occur with the use of this product would be hypotension, dizziness or syncope. Patients who are currently being treated with prescription medications for high blood pressure or enlarged prostate would be at increased risk of these events. In these patients, the hypotensive events may be more severe. No illnesses have been reported to the company to date in connection with this product.

The product has been distributed nationwide via retail stores, internet sales and mail order. All of the following U-Prosta products, which are packaged in white plastic bottles & 1 capsule blister pack, are involved in this voluntary recall:

PRODUCT PACKAGE SIZE UPC CODES
U-Prosta Dietary Supplement  30 Capsules 689076499255
U-Prosta Dietary Supplement  60 Capsules 88858100030
U-Prosta Dietary Supplement  1 Capsule No UPC Code

Consumers in possession of the affected product are urged to stop using it immediately and return it to the place of purchase for a full refund. Consumers with questions may contact USA Far Ocean Group, Inc. Special Recall number at 626-576-1299, Monday through Sunday, between 9 a.m. and 5 p.m. Pacific Standard Time. Consumers should contact their physician if they have experienced any problem that may be related to taking this product. Any adverse reactions experienced with the use of this product, and/or quality problems should also be reported to the FDA's MedWatch Program by:

  • Online: www.fda.gov/medwatch/report.htm
  • Fax: 1-800-FDA-0178
  • Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm
  • Mail to: MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787

USA Far Ocean Group Inc. is located at 1609 W. Valley Blvd., #338, Alhambra, CA 91803.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Review Date: 
March 24, 2011